Details for New Drug Application (NDA): 202211
✉ Email this page to a colleague
The generic ingredient in OXYTROL FOR WOMEN is oxybutynin. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxybutynin profile page.
Summary for 202211
Tradename: | OXYTROL FOR WOMEN |
Applicant: | Abbvie |
Ingredient: | oxybutynin |
Patents: | 0 |
Pharmacology for NDA: 202211
Mechanism of Action | Cholinergic Muscarinic Antagonists |
Suppliers and Packaging for NDA: 202211
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
OXYTROL FOR WOMEN | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 202211 | NDA | Allergan, Inc. | 0023-9637 | 0023-9637-04 | 16 PATCH in 1 CARTON (0023-9637-04) / 4 d in 1 PATCH |
OXYTROL FOR WOMEN | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 202211 | NDA | Allergan, Inc. | 0023-9637 | 0023-9637-08 | 32 PATCH in 1 CARTON (0023-9637-08) / 4 d in 1 PATCH |
Profile for product number 001
Active Rx/OTC/Discontinued: | OTC | Dosage: | FILM, EXTENDED RELEASE;TRANSDERMAL | Strength | 3.9MG/24HR | ||||
Approval Date: | Jan 25, 2013 | TE: | RLD: | Yes |
Expired US Patents for NDA 202211
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | OXYTROL FOR WOMEN | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 202211-001 | Jan 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | OXYTROL FOR WOMEN | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 202211-001 | Jan 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | OXYTROL FOR WOMEN | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 202211-001 | Jan 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | OXYTROL FOR WOMEN | oxybutynin | FILM, EXTENDED RELEASE;TRANSDERMAL | 202211-001 | Jan 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription